KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Operating Leases (2020 - 2025)

Historic Operating Leases for Vir Biotechnology (VIR) over the last 6 years, with Q3 2025 value amounting to $91.2 million.

  • Vir Biotechnology's Operating Leases fell 234.46% to $91.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.2 million, marking a year-over-year decrease of 234.46%. This contributed to the annual value of $90.1 million for FY2024, which is 2762.25% down from last year.
  • According to the latest figures from Q3 2025, Vir Biotechnology's Operating Leases is $91.2 million, which was down 234.46% from $93.4 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Operating Leases high stood at $133.6 million for Q4 2021, and its period low was $66.6 million during Q1 2021.
  • In the last 5 years, Vir Biotechnology's Operating Leases had a median value of $109.2 million in 2024 and averaged $105.0 million.
  • In the last 5 years, Vir Biotechnology's Operating Leases skyrocketed by 46735.03% in 2021 and then plummeted by 2762.25% in 2024.
  • Quarter analysis of 5 years shows Vir Biotechnology's Operating Leases stood at $133.6 million in 2021, then decreased by 4.18% to $128.0 million in 2022, then decreased by 2.68% to $124.5 million in 2023, then dropped by 27.62% to $90.1 million in 2024, then grew by 1.19% to $91.2 million in 2025.
  • Its last three reported values are $91.2 million in Q3 2025, $93.4 million for Q2 2025, and $88.2 million during Q1 2025.